Roche Corporation announced today that the FDA has approved the FoundationOne CDx ™ Foundation's comprehensive companion diagnostic method for personalized oncology treatment1
Roche has announced the launch of the NAVIFY Tumor Board solution, a clinical workflow and decision support software that optimises decision-making for cancer patient case reviews in tumor boards, or multi-disciplinary team meetings.
The US Food and Drug Administration (FDA) granted accelerated approval to a treatment for patients whose cancers have a specific genetic feature (biomarker).